The ASCO Annual Meeting, which will be held June 3–7, 2016, in Chicago, brings together more than 30,000 oncology professionals from around the world to learn about and discuss the latest therapies, treatment modalities, research, and controversies in the field. Attendees are able to personalize their meeting experience by choosing from a wide variety of session types and topics.
Ticketed sessions, including Meet the Professor (MTP) and Clinical Problems in Oncology (CPO), give attendees the opportunity to interact with experts and focus their learning in an intimate setting.
Meet the Professor Sessions
MTP Sessions enable interactive discussion between attendees and recognized experts in a variety of subspecialty fields. The format is informal, with an emphasis on a face-to-face exchange with the expert, and sessions are limited to 75 attendees to allow for ample networking time.
2016 MTP Sessions include:
- Complex Decision-Making in Clinical Practice: Interpreting HER2 Results
- Treatment of Medulloblastoma: The Devil Is in the Details
- Imaging in Rectal Cancer
- Systemic and Surgical Considerations in Upper Tract Transitional Cell Carcinoma
- Radium 223 in the Management of Castration-Resistant Prostate Cancer
- Cervical Cancer Screening and Prevention in Low-Resource Countries
- Current State of Functional Organ Preservation in Head and Neck Cancer
- Inside the Minds of Patients: Incorporating Patient-Reported Outcomes Into Clinical Trials
- Management of Acute Lymphoblastic Leukemia in Adolescent and Young Adult Patients
- Diffuse Large B-Cell Lymphoma: When to Refer Patients for Radiation Therapy
- Initial Therapy for Older Patients With Chronic Lymphocytic Leukemia
- How I Treat High-Risk Multiple Myeloma
- Melanoma Immunotherapy: Where Do We Go From Here?
- The Peer-Review Process and Writing an Outstanding Manuscript
- GISTs and Beyond: New Targets and Novel Therapies
- The Liquid Biopsy: Breaking Out the Key Components
Clinical Problems in Oncology Sessions
CPO Sessions combine case-based panel discussions with real-time audience participation. Attendees submit responses to questions based on real-world scenarios using keypads, enabling them to interact with session content and immediately gauge their own understanding of content.
2016 CPO Sessions include:
- Testicular Cancer: A Multidisciplinary Case-Based Discussion
- Tumor Board on Systemic Therapies for Metastatic Prostate Cancer: Induction, Maintenance, and Sequencing
- Challenging Cases in the Management of Head and Neck Cancer
- Rare Plasma Cell Dyscrasia: Amyloid, Monoclonal Gammopathy of Renal Significance, and Waldenström Macroglobulinemia
- Now That We Have Immunotherapy, What Do We Do?
- Real-World Issues Using Immunotherapy and Targeted Therapies in Melanoma
- Practical Tips to Engage Your Trainees, Advanced-Practice Providers, and Patients
- Case Studies From the Frontline: Building Leadership Skills to Resolve Conflicts
- The Role of Chemotherapy in the Neoadjuvant, Adjuvant, and Metastatic Settings for Patients With Soft-Tissue Sarcoma: Where Do We Stand in 2016?
As a ticketed session attendee, you’ll receive exclusive access to eCPO on ASCO.org. eCPO content will include the slides, audio, and audience participation results from each CPO session.
Adding the Ticketed Session Package to your Annual Meeting registration is the only way to gain access to these specialized sessions. The package includes preregistration for one CPO or MTP session, admission to any CPO or MTP session if seats remain 5 minutes after the scheduled start time, the ability to purchase additional tickets for an unlimited number of sessions, and access to online content from each CPO session after the meeting.
Early registration is encouraged, as attendance in these sessions is limited. The Ticketed Session Package is $70 for ASCO members and $85 for nonmembers before May 20. Additional tickets can be purchased for $25 (ASCO members) or $35 (nonmembers).
To learn more and register for the Annual Meeting with the Ticketed Session Package, visit am.asco.org. ■
© 2016. American Society of Clinical Oncology. All rights reserved.
